Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound doubled in the fourth quarter year over year, despite ...

The Zepbound LillyDirect offers comes in a single-dose vial rather than as an auto-injector pen, also called a Zepbound pen. The vial doses available are 2.5 mg and 5 mg, which is limited compared ...

A diabetes drug may beat costly shots for patients with a rare genetic condition, according to a Rutgers Health study.

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

while Wegovy is a weekly injection. Do you need a prescription for Zepbound? Yes, you need a prescription for Zepbound. Prescriptions can typically be written by licensed healthcare professionals ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...

Eli Lilly will announce Q4 2024 results, with analysts estimating $13.7 billion in sales and $4.94 EPS, alongside a revenue growth outlook for 2024.